CymaBay Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for liver and metabolic diseases. Their lead product candidate, seladelpar, is being evaluated for the treatment of primary biliary cholangitis and nonalcoholic steatohepatitis, potentially addressing unmet medical needs in these patient populations. With a strong pipeline and innovative approach, CymaBay Therapeutics is poised to make a significant impact in the field of liver and metabolic diseases.
Notification